A safe harbour?, page-3

OriginallypostedbyBillGates

Nobodywhowantstostayinpowerwillwanttoseethesightofbodiesinthestreetsagainandhospitalsthancannotcopewiththissortofthing.

Iseeallcountriesbeefinguptheirdefencesmassivelyagainstthesepandemicstoatleastappeartobecompetent,betheymanmadepandemics,orotherwise....

Can't wait until we get PLA tender info and eventual US and European sales...

Some excerpts from the Alan Kohler interview in late March -

"The Society for Critical Care Medicine, which is a US body, 25-30 per cent of the authors all use Uscom. While we’re not the only device, we are the one that’s most effective."

"Although, currently we’re in a number of PLA tenders that are for very large sectors of the Chinese economy. They’re saying, “Seasonal infections are a fact of life. Corona will come and go, but flus will come each year.” As we already know, the flu mortality in the US, not last year but the year before, did excess of 63,000. 43 million people were infected, 60,000 died and 810,000 were hospitalised. These are massive, massive, massive numbers."

"China, who are leading all of this stuff, are actually now upgrading both the stent and the equipment within many of their ICUs. The US are talking about it but they won’t get a chance to do it for at least another six months, once they get through the whole COVID clinical crisis stage."

"I’ve actively enhanced – we have a manufacturing company that we bought in Budapest, which is the spirometry company, so what I’m doing now is actively building up that distribution network in Europe. It’s just that China was the first path and it’s the one that had the most obvious returns for us, and it was the strongest."

"Europe’s coming ahead now – and it’s hard to be sure because of the COVID complication. But also in the US, we’ve had our own organisation there for five or six years, but it’s been a tough time for us. We’ve just adopted a totally different model now and we have distribution based partnerships that now cover 80 per cent of the US. That’s only just been signed up two months ago, so we actually don’t know what the effects of that are. But we know these are really good distributors, our products are really good and the COVID issue can only enhance our prominence. Also, just the recent Society of Critical Care Medicine endorsement of the product will change our opportunity. Ultimately, we’ll be a global company, not a Chinese company."

"Hopefully, NMPA approval will come through probably June to December and then we’ll have additional cash flow apart from Uscom 1A, as well as European cash flow should start coming back once COVID settles down over there and the same out of the US, because each of those devices are all going into those markets. The opportunities for growth are quite astounding, but it’s all about execution. We seem to have got a plan. We’ve been in the market long enough to learn and as you know, CSL was established in 1916, ResMed 1980 and Cochlear a similar time."

GLTAH